We claim:

1) An isolated human or human-adapted antibody antagonist or fragment thereof that specifically binds Domain I (SEQ ID NO: 9) of human ST2L.

2) The isolated antibody of claim 1, wherein the antibody blocks IL-33/ST2L interaction.

3) The isolated antibody of claim 2 having a dissociation constant (K_D) to human ST2L between about $5x10^{-12}$ M to about $7x10^{-10}$ M, an on rate constant (K_{on}) to human ST2L between about $2x10^6$ $M^{-1}s^{-1}$ to about $1x10^8$ $M^{-1}s^{-1}$, or an off rate constant (K_{off}) to human ST2L between about $1x10^{-6}$ s^{-1} to about $1x10^{-2}$ s^{-1}.

4) The isolated antibody of claim 3 having a dissociation constant (K_D) to *Macaca fascicularis* (cyno) ST2L (SEQ ID NO: 2) between about $3x10^{-12}$ M to about $2x10^{-9}$ M, an on rate constant (K_{on}) to cyno ST2L between about $4x10^6$ $M^{-1}s^{-1}$ to about $1x10^8$ $M^{-1}s^{-1}$, or an off rate constant (K_{off}) to cyno ST2L between about $7x10^{-5}s^{-1}$ to about $1x10^{-1}s^{-1}$.

5) The isolated antibody of claim 4 comprising:

a) a heavy chain complementarity determining region (HCDR) 1 (HCDR1) of SEQ ID NO: 160 ($X_1X_2X_3MX_4$); wherein

X_1 is S, F, D, I, G or V;

X_2 is Y or D;

X_3 is A, D or S; and

X_4 is S, F or I;

b) a HCDR 2 (HCDR2) of SEQ ID NO: 161 ($X_5IX_6GX_7GGX_8TX_9YADSVKG$); wherein

X_5 is A, S, T, Y or D;

X_6 is S, R, E, K, G or A;

X_7 is S, E or N;

X_8 is S, R, E, G, T, D or A; and

X_9 is Y, D, N, A or S; and

c) a HCDR 3 (HCDR3) of SEQ ID NO: 162 ($X_{10}X_{11}$WSTEGSFFVLDY); wherein

X_{10} is D, A, R, N, Q, P, E, I, H, S, T or Y; and

X_{11} is P, A, H, Y, E, Q, L, S, N, T, V, or I; and

d) a light chain complementarity determining region (LCDR) 1 (LCDR1) of SEQ ID NO: 163 (RASQSVDDX_{12}LA); wherein

X_{12} is A or D;

e) a LCDR 2 (LCDR2) of SEQ ID NO: 90 (DASNRAT); and

f) a LCDR 3 (LCDR3) of SEQ ID NO: 164 (QQ$X_{13}X_{14}X_{15}X_{16}X_{17}X_{18}$T); wherein

X_{13} is F or Y;

X_{14} is Y, I or N;

X_{15} is N, G, D or T;

X_{16} is W or A;

X_{17} is P or deleted; and

X_{18} is L or I.

6) The isolated antibody of claim 5, comprising:

a) the HCDR1 of SEQ ID NO: 97;

b) the HCDR2 of SEQ ID NO: 114;

c) the HCDR3 of SEQ ID NO: 84;

d) the LCDR1 of SEQ ID NO: 130;

e) the LCDR2 of SEQ ID NO: 90; and

f) the LCDR3 of SEQ ID NO: 134; or

g) the VH of SEQ ID NO: 191 and the VL of SEQ ID NO: 209.

7) The isolated antibody of claim 5 comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of:

a) SEQ ID NOs: 78, 81, 84, 87, 90 and 92, respectively;

b) SEQ ID NOs: 78, 81, 84, 130, 90 and 131, respectively;

c) SEQ ID NOs: 78, 81, 84, 130, 90 and 132, respectively;

d) SEQ ID NOs: 78, 81, 84, 130, 90 and 133, respectively;

e) SEQ ID NOs: 78, 81, 84, 130, 90 and 134, respectively;

f) SEQ ID NOs: 95, 109, 84, 130, 90 and 131, respectively;

g) SEQ ID NOs: 96, 110, 84, 130, 90 and 131, respectively;

h) SEQ ID NOs: 97, 111, 84, 130, 90 and 131, respectively;

i) SEQ ID NOs: 96, 110, 84, 130, 90 and 134, respectively;

j) SEQ ID NOs: 97, 111, 84, 130, 90 and 134, respectively;

k) SEQ ID NOs: 97, 112, 84, 130, 90 and 134, respectively;

l) SEQ ID NOs: 98, 113, 84, 130, 90 and 134, respectively;

m) SEQ ID NOs: 97, 114, 84, 130, 90 and 134, respectively;

n) SEQ ID NOs: 97, 115, 84, 130, 90 and 134, respectively;

o) SEQ ID NOs: 99, 116, 84, 130, 90 and 133, respectively;

p) SEQ ID NOs: 100, 117, 84, 130, 90 and 133, respectively;

q) SEQ ID NOs: 101, 118, 84, 130, 90 and 133, respectively;

r) SEQ ID NOs: 102, 120, 84, 130, 90 and 132, respectively;

s) SEQ ID NOs: 103, 121, 84, 130, 90 and 132, respectively;

t) SEQ ID NOs: 103, 122, 84, 130, 90 and 131, respectively;

u) SEQ ID NOs: 103, 123, 84, 130, 90 and 131, respectively;

v) SEQ ID NOs: 104, 124, 84, 130, 90 and 131, respectively;

w) SEQ ID NOs: 105, 125, 84, 130, 90 and 131, respectively;

x) SEQ ID NOs: 106, 126, 84, 130, 90 and 131, respectively;

y) SEQ ID NOs: 95, 127, 84, 130, 90 and 131, respectively;

z) SEQ ID NOs: 107, 128, 84, 130, 90 and 131, respectively;

aa) SEQ ID NOs: 108, 129, 84, 130, 90 and 131, respectively;

bb) SEQ ID NOs: 97, 114, 165, 130, 90 and 134, respectively;

cc) SEQ ID NOs: 97, 114, 166, 130, 90 and 134, respectively;

dd) SEQ ID NOs: 97, 114, 167, 130, 90 and 134, respectively;

ee) SEQ ID NOs: 97, 114, 168, 130, 90 and 134, respectively;

ff) SEQ ID NOs: 97, 114, 169, 130, 90 and 134, respectively;

gg) SEQ ID NOs: 97, 114, 170, 130, 90 and 134, respectively;

hh) SEQ ID NOs: 97, 114, 171, 130, 90 and 134, respectively;

ii) SEQ ID NOs: 97, 114, 172, 130, 90 and 134, respectively;

jj) SEQ ID NOs: 97, 114, 173, 130, 90 and 134, respectively;

kk) SEQ ID NOs: 97, 114, 174, 130, 90 and 134, respectively;

ll) SEQ ID NOs: 97, 114, 175, 130, 90 and 134, respectively;

mm) SEQ ID NOs: 97, 114, 176, 130, 90 and 134, respectively;

nn) SEQ ID NOs: 97, 114, 177, 130, 90 and 134, respectively;

oo) SEQ ID NOs: 97, 114, 178, 130, 90 and 134, respectively;

pp) SEQ ID NOs: 97, 114, 179, 130, 90 and 134, respectively;

qq) SEQ ID NOs: 97, 114, 180, 130, 90 and 134, respectively;

rr) SEQ ID NOs: 97, 114, 181, 130, 90 and 134, respectively;

ss) SEQ ID NOs: 97, 114, 182, 130, 90 and 134, respectively;

tt) SEQ ID NOs: 97, 114, 183, 130, 90 and 134, respectively;

uu) SEQ ID NOs: 97, 114, 184, 130, 90 and 134, respectively; or

vv) SEQ ID NOs: 97, 114, 185, 130, 90 and 134, respectively.

8) The isolated antibody of claim 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of:

a) SEQ ID NOs: 23, 27, 31, 35, 39 and 43, respectively;

b) SEQ ID NOs: 24, 28, 32, 36, 40 and 44, respectively;

c) SEQ ID NOs: 24, 28, 146, 36, 40 and 147, respectively; or

d) SEQ ID NOs: 24, 28, 146, 36, 40 and 44, respectively.

9) The isolated antibody of claim 2, wherein the antibody competes for binding to human ST2L (SEQ ID NO: 1) with an isolated antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 47 and a light chain variable region (VL) of SEQ ID NO: 51.

10) The isolated antibody of claim 9, wherein the antibody binds human ST2L at amino acid residues 35-48 of SEQ ID NO: 1 (RCPRQGKPSYTVDW; SEQ ID NO: 210).

11) The isolated antibody of claim 10, wherein the antibody further binds human ST2L at amino acid residues T93 and F94 of SEQ ID NO: 1.

12) The isolated antibody of claim 1, comprising a heavy chain variable region (VH) comprising a VH framework derived from human IGHV3-23 (SEQ ID NO: 158), IGHV1-24*01 (SEQ ID NO: 148) or IGHV1-f*01 (SEQ ID NO: 149) framework sequences, and a light chain variable region (VL) comprising a VL framework derived from a human IGKV3-11 (L6) (SEQ ID NO: 159), IGKV3-15*01 (L2) (SEQ ID NO: 150), IGKV1-9*01 (L8) (SEQ ID NO: 151), IGKV1-5*01 (L1) (SEQ ID NO: 152), IGKV1-12*01 (L5) (SEQ ID NO: 153), IGKV1-39*01 (O12) (SEQ ID NO: 154), IGKV1-27*01 (A20) (SEQ ID NO: 155)or IGKV1-33*01 (O18) (SEQ ID NO: 156) framework sequences.

13) The isolated antibody of claim 1 which is of IgG1, IgG2, IgG3, or IgG4 type.

14) The isolated antibody of claim 13 having a substitution in an Fc region.

15) The isolated antibody of claim 14, wherein the substitution comprises a substitution M252Y/S254T/T256E, V234A/G237A/P238S/H28A/V309L/A330S/P331S or P238S/L234A/L235A, wherein residue numbering is according to the EU numbering.

16) The isolated antibody of claim 12 comprising the VH at least 90% identical to the VH of SEQ ID NO: 191 and the VL at least 94% identical to the VL of SEQ ID NO: 209.

17) The isolated antibody of claim 16 comprising the VH of SEQ ID NOs: 143, 144, 145, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204 or 205 and the VL of SEQ ID NOs: 135, 136, 137, 138, 139, 140, 141, 142, 206, 207, 208 or 209.

18) The isolated antibody of claim 17, comprising the VH and the VL of:

a) SEQ ID NO: 186 and SEQ ID NO: 206, respectively;

b) SEQ ID NO: 187 and SEQ ID NO: 206, respectively;

c) SEQ ID NO: 197 and SEQ ID NO: 206, respectively;

d) SEQ ID NO: 198 and SEQ ID NO: 206, respectively;

e) SEQ ID NO: 199 and SEQ ID NO: 206, respectively;

f) SEQ ID NO: 200 and SEQ ID NO: 206, respectively;

g) SEQ ID NO: 201 and SEQ ID NO: 206, respectively;

h) SEQ ID NO: 202 and SEQ ID NO: 206, respectively;

i) SEQ ID NO: 203 and SEQ ID NO: 206, respectively;

j) SEQ ID NO: 204 and SEQ ID NO: 206, respectively;

k) SEQ ID NO: 205 and SEQ ID NO: 206, respectively;

l) SEQ ID NO: 195 and SEQ ID NO: 207, respectively;

m) SEQ ID NO: 196 and SEQ ID NO: 207, respectively;

n) SEQ ID NO: 188 and SEQ ID NO: 208, respectively;

o) SEQ ID NO: 189 and SEQ ID NO: 208, respectively;

p) SEQ ID NO: 190 and SEQ ID NO: 208, respectively;

q) SEQ ID NO: 187 and SEQ ID NO: 209, respectively;

r) SEQ ID NO: 191 and SEQ ID NO: 209, respectively;

s) SEQ ID NO: 192 and SEQ ID NO: 209, respectively;

t) SEQ ID NO: 193 and SEQ ID NO: 209, respectively;

or

u) SEQ ID NO: 194 and SEQ ID NO: 209, respectively.

19) An isolated polynucleotide encoding the VH of SEQ ID NOs: 143, 144, 145, 186, 187, 197, 198, 199, 200, 201, 202, 203, 204 or 205, or the VL of SEQ ID NOs: 135, 136, 137, 138, 139, 140, 141, 142, 206, 207, 208 or 209.

20) A vector comprising an isolated polynucleotide of claim 19.

21) A host cell comprising a vector of claim 20.

22) A method of producing an antibody of claim 18, comprising culturing a host cell of claim 21 and recovering the antibody from the cell.

23) A pharmaceutical composition comprising an isolated antibody of claim 1 or claim 6 and a pharmaceutically accepted carrier.

24) A method of treating or preventing a ST2L-mediated condition comprising administering a therapeutically effective amount of an isolated antibody of claim 1 or claim 6 to a patient in need thereof for a time sufficient to treat or prevent the ST2L-mediated condition.

25) The method of claim 24, wherein the ST2L-mediated condition is asthma, airway hyper-reactivity, sarcoidosis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, inflammatory bowel disease, (IBD), eosinophilic esophagitis, scleroderma, atopic dermatitis, allergic rhinitis, bullous pemphigoid, chronic urticaria, diabetic nephropathy, rheumatoid arthritis, interstitial cystitis or Graft Versus Host Disease (GVHD), or is is associated with inflammatory

cell recruitment in lung, goblet cell hyperplasia, increased mucous secretion or mast cell response.

26) A method of inhibiting mast cell response in a patient comprising administering a therapeutically effective amount of an isolated antibody of claim 1 to a patient in need thereof for a time sufficient to inhibit the mast cell response.

27) The method of claim 26, wherein the inhibiting mast cell response comprises inhibiting the level of GM-CSF, IL-5, IL-8, IL-10 or IL-13 released by human cord blood-derived mast cells by at least 50% with 50 μg/ml antibody.

28) A method of inhibiting interaction of IL-33 and ST2L in a subject, comprising administering to the subject an antibody that specifically binds domain I of ST2L in an amount sufficient to inhibit the interaction of IL-33 and ST2L.

29) The method of claim 28, wherein the subject has a ST2L-mediated condition.

30) The method of claim 29, wherein the ST2L-mediated condition is asthma, airway hyper-reactivity, sarcoidosis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, inflammatory bowel disease, (IBD), eosinophilic esophagitis, scleroderma, atopic dermatitis, allergic rhinitis, bullous pemphigoid, chronic urticaria, diabetic nephropathy, rheumatoid arthritis, interstitial cystitis or Graft Versus Host Disease (GVHD), or isassociated with inflammatory cell recruitment in lung, goblet cell hyperplasia, or increased mucous secretion, or mast cell response.

31) The method of claim 29, wherein the antibody comprises:

a) the HCDR1 of SEQ ID NO: 97;

b) the HCDR2 of SEQ ID NO: 114;

c) the HCDR3 of SEQ ID NO: 84;

d) the LCDR1 of SEQ ID NO: 130;

e) the LCDR2 of SEQ ID NO: 90; and

f) the LCDR3 of SEQ ID NO: 134; or

g) the VH of SEQ ID NO: 191 and the VL of SEQ ID NO: 209.

32) The antibody of claim 1, claim 6 or claim 9 for use in therapy.

CLAIMS

1) An isolated human or human-adapted antibody antagonist or fragment thereof that specifically binds Domain I (SEQ ID NO: 9) of human ST2L, comprising:

a) a heavy chain complementarity determining region (HCDR) 1 (HCDR1)of SEQ ID NO: 160 ($X_1X_2X_3MX_4$); wherein

X_1 is S, F, D, I, G or V;

X_2 is Y or D;

X_3 is A, D or S; and

X_4 is S, F or I;

b) a HCDR 2 (HCDR2) of SEQ ID NO: 161 ($X_5IX_6GX_7GGX_8TX_9YADSVKG$); wherein

X_5 is A, S, T, Y or D;

X_6 is S, R, E, K, G or A;

X_7 is S, E or N;

X_8 is S, R, E, G, T, D or A; and

X_9 is Y, D, N, A or S;

c) a HCDR 3 (HCDR3) of SEQ ID NO: 162 ($X_{10}X_{11}$WSTEGSFFVLDY); wherein

X_{10} is D, A, R, N, Q, P, E, I, H, S, T or Y; and

X_{11} is P, A, H, Y, E, Q, L, S, N, T, V, or I;

d) a light chain complementarity determining region (LCDR) 1 (LCDR1) of SEQ ID NO: 163 (RASQSVDDX_{12}LA); wherein

X_{12} is A or D;

e) a LCDR 2 (LCDR2) of SEQ ID NO: 90 (DASNRAT); and

f) a LCDR 3 (LCDR3) of SEQ ID NO: 164 (QQ$X_{13}X_{14}X_{15}X_{16}X_{17}X_{18}$T); wherein

X_{13} is F or Y;

X_{14} is Y, I or N;

X_{15} is N, G, D or T;

X_{16} is W or A;

X_{17} is P or deleted; and

X_{18} is L or I.

2) The isolated antibody of claim 1, wherein the antibody blocks IL-33/ST2L interaction.

3) The isolated antibody of claim 2 having a dissociation constant (K_D) to human ST2L between about $5x10^{-12}$ M to about $7x10^{-10}$ M, an on rate constant (K_{on}) to human ST2L between about $2x10^6$ $M^{-1}s^{-1}$ to about $1x10^8$ $M^{-1}s^{-1}$, or an off rate constant (K_{off}) to human ST2L between about $1x10^{-6}$ s^{-1} to about $1x10^{-2}$ s^{-1}.

4) The isolated antibody of claim 3 having a dissociation constant (K_D) to *Macaca fascicularis* (cyno) ST2L (SEQ ID NO: 2) between about $3x10^{-12}$ M to about $2x10^{-9}$ M, an on rate constant (K_{on}) to cyno ST2L between about $4x10^6$ $M^{-1}s^{-1}$ to about $1x10^8$ $M^{-1}s^{-1}$, or an off rate constant (K_{off}) to cyno ST2L between about $7x10^{-5}s^{-1}$ to about $1x10^{-1}s^{-1}$.

5) The isolated antibody of claim 4, comprising:

a) the HCDR1 of SEQ ID NO: 97;

b) the HCDR2 of SEQ ID NO: 114;

c) the HCDR3 of SEQ ID NO: 84;

d) the LCDR1 of SEQ ID NO: 130;

e) the LCDR2 of SEQ ID NO: 90; and

f) the LCDR3 of SEQ ID NO: 134; or

g) the VH of SEQ ID NO: 191 and the VL of SEQ ID NO: 209.

6) The isolated antibody of claim 4 comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of:

a) SEQ ID NOs: 78, 81, 84, 87, 90 and 92, respectively;

b) SEQ ID NOs: 78, 81, 84, 130, 90 and 131, respectively;

c) SEQ ID NOs: 78, 81, 84, 130, 90 and 132, respectively;

d) SEQ ID NOs: 78, 81, 84, 130, 90 and 133, respectively;

e) SEQ ID NOs: 78, 81, 84, 130, 90 and 134, respectively;

f) SEQ ID NOs: 95, 109, 84, 130, 90 and 131, respectively;

g) SEQ ID NOs: 96, 110, 84, 130, 90 and 131, respectively;

h) SEQ ID NOs: 97, 111, 84, 130, 90 and 131, respectively;

i) SEQ ID NOs: 96, 110, 84, 130, 90 and 134, respectively;

j) SEQ ID NOs: 97, 111, 84, 130, 90 and 134, respectively;

k) SEQ ID NOs: 97, 112, 84, 130, 90 and 134, respectively;

l) SEQ ID NOs: 98, 113, 84, 130, 90 and 134, respectively;

m) SEQ ID NOs: 97, 114, 84, 130, 90 and 134, respectively;

n) SEQ ID NOs: 97, 115, 84, 130, 90 and 134, respectively;

o) SEQ ID NOs: 99, 116, 84, 130, 90 and 133, respectively;

p) SEQ ID NOs: 100, 117, 84, 130, 90 and 133, respectively;

q) SEQ ID NOs: 101, 118, 84, 130, 90 and 133, respectively;

r) SEQ ID NOs: 102, 120, 84, 130, 90 and 132, respectively;

s) SEQ ID NOs: 103, 121, 84, 130, 90 and 132, respectively;

t) SEQ ID NOs: 103, 122, 84, 130, 90 and 131, respectively;

u) SEQ ID NOs: 103, 123, 84, 130, 90 and 131, respectively;

v) SEQ ID NOs: 104, 124, 84, 130, 90 and 131, respectively;

w) SEQ ID NOs: 105, 125, 84, 130, 90 and 131, respectively;

x) SEQ ID NOs: 106, 126, 84, 130, 90 and 131, respectively;

y) SEQ ID NOs: 95, 127, 84, 130, 90 and 131, respectively;

z) SEQ ID NOs: 107, 128, 84, 130, 90 and 131, respectively;

aa) SEQ ID NOs: 108, 129, 84, 130, 90 and 131, respectively;

bb) SEQ ID NOs: 97, 114, 165, 130, 90 and 134, respectively;

cc) SEQ ID NOs: 97, 114, 166, 130, 90 and 134, respectively;

dd) SEQ ID NOs: 97, 114, 167, 130, 90 and 134, respectively;

ee) SEQ ID NOs: 97, 114, 168, 130, 90 and 134, respectively;

ff) SEQ ID NOs: 97, 114, 169, 130, 90 and 134, respectively;

gg) SEQ ID NOs: 97, 114, 170, 130, 90 and 134, respectively;

hh) SEQ ID NOs: 97, 114, 171, 130, 90 and 134, respectively;

ii) SEQ ID NOs: 97, 114, 172, 130, 90 and 134, respectively;

jj) SEQ ID NOs: 97, 114, 173, 130, 90 and 134, respectively;

kk) SEQ ID NOs: 97, 114, 174, 130, 90 and 134, respectively;

ll) SEQ ID NOs: 97, 114, 175, 130, 90 and 134, respectively;

mm) SEQ ID NOs: 97, 114, 176, 130, 90 and 134, respectively;

nn) SEQ ID NOs: 97, 114, 177, 130, 90 and 134, respectively;

oo) SEQ ID NOs: 97, 114, 178, 130, 90 and 134, respectively;

pp) SEQ ID NOs: 97, 114, 179, 130, 90 and 134, respectively;

qq) SEQ ID NOs: 97, 114, 180, 130, 90 and 134, respectively;

rr) SEQ ID NOs: 97, 114, 181, 130, 90 and 134, respectively;

ss) SEQ ID NOs: 97, 114, 182, 130, 90 and 134, respectively;

tt) SEQ ID NOs: 97, 114, 183, 130, 90 and 134, respectively;

uu) SEQ ID NOs: 97, 114, 184, 130, 90 and 134, respectively; or

vv) SEQ ID NOs: 97, 114, 185, 130, 90 and 134, respectively.

7) The isolated antibody of claim 4, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of:
a) SEQ ID NOs: 23, 27, 31, 35, 39 and 43, respectively;
b) SEQ ID NOs: 24, 28, 32, 36, 40 and 44, respectively;
c) SEQ ID NOs: 24, 28, 146, 36, 40 and 147, respectively; or
d) SEQ ID NOs: 24, 28, 146, 36, 40 and 44, respectively.

8) The isolated antibody of claim 4, wherein the antibody competes for binding to human ST2L (SEQ ID NO: 1) with an isolated antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 47 and a light chain variable region (VL) of SEQ ID NO: 51.

9) The isolated antibody of claim 8, wherein the antibody binds human ST2L at amino acid residues 35-48 of SEQ ID NO: 1 (RCPRQGKPSYTVDW; SEQ ID NO: 210).

10) The isolated antibody of claim 9, wherein the antibody further binds human ST2L at amino acid residues T93 and F94 of SEQ ID NO: 1.

11) The isolated antibody of claim 1, comprising a heavy chain variable region (VH) comprising a VH framework derived from human IGHV3-23 (SEQ ID NO: 158), IGHV1-24*01 (SEQ ID NO: 148) or IGHV1-f*01 (SEQ ID NO: 149) framework sequences, and a light chain variable region (VL) comprising a VL framework derived from a human IGKV3-11 (L6) (SEQ ID NO: 159), IGKV3-15*01 (L2) (SEQ ID NO: 150), IGKV1-9*01 (L8) (SEQ ID NO: 151), IGKV1-5*01 (L12) (SEQ ID NO: 152), IGKV1-12*01 (L5) (SEQ ID NO: 153), IGKV1-39*01 (O12) (SEQ ID NO: 154), IGKV1-27*01 (A20) (SEQ ID NO: 155)or IGKV1-33*01 (O18) (SEQ ID NO: 156) framework sequences.

12) The isolated antibody of claim 1 which is of IgG1, IgG2, IgG3, or IgG4 type.

13) The isolated antibody of claim 12 having a substitution in an Fc region.

14) The isolated antibody of claim 13, wherein the substitution comprises a substitution M252Y/S254T/T256E, V234A/G237A/P238S/H28A/V309L/A330S/P331S or P238S/L234A/L235A, wherein residue numbering is according to the EU numbering.

15) The isolated antibody of claim 11 comprising the VH at least 90% identical to the VH of SEQ ID NO: 191 and the VL at least 94% identical to the VL of SEQ ID NO: 209.

16) The isolated antibody of claim 15 comprising the VH of SEQ ID NOs: 143, 144, 145, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204 or 205 and the VL of SEQ ID NOs: 135, 136, 137, 138, 139, 140, 141, 142, 206, 207, 208 or 209.

17) The isolated antibody of claim 16, comprising the VH and the VL of:

a) SEQ ID NO: 186 and SEQ ID NO: 206, respectively;

b) SEQ ID NO: 187 and SEQ ID NO: 206, respectively;

c) SEQ ID NO: 197 and SEQ ID NO: 206, respectively;

d) SEQ ID NO: 198 and SEQ ID NO: 206, respectively;

e) SEQ ID NO: 199 and SEQ ID NO: 206, respectively;

f) SEQ ID NO: 200 and SEQ ID NO: 206, respectively;

g) SEQ ID NO: 201 and SEQ ID NO: 206, respectively;

h) SEQ ID NO: 202 and SEQ ID NO: 206, respectively;

i) SEQ ID NO: 203 and SEQ ID NO: 206, respectively;

j) SEQ ID NO: 204 and SEQ ID NO: 206, respectively;

k) SEQ ID NO: 205 and SEQ ID NO: 206, respectively;

l) SEQ ID NO: 195 and SEQ ID NO: 207, respectively;

m) SEQ ID NO: 196 and SEQ ID NO: 207, respectively;

n) SEQ ID NO: 188 and SEQ ID NO: 208, respectively;

o) SEQ ID NO: 189 and SEQ ID NO: 208, respectively;

p) SEQ ID NO: 190 and SEQ ID NO: 208, respectively;

q) SEQ ID NO: 187 and SEQ ID NO: 209, respectively;

r) SEQ ID NO: 191 and SEQ ID NO: 209, respectively;

s) SEQ ID NO: 192 and SEQ ID NO: 209, respectively;

t) SEQ ID NO: 193 and SEQ ID NO: 209, respectively; or

u) SEQ ID NO: 194 and SEQ ID NO: 209, respectively.

18) An isolated polynucleotide encoding the VH of SEQ ID NOs: 143, 144, 145, 186, 187, 197, 198, 199, 200, 201, 202, 203, 204 or 205, or the VL of SEQ ID NOs: 135, 136, 137, 138, 139, 140, 141, 142, 206, 207, 208 or 209.

19) A vector comprising an isolated polynucleotide of claim 18.

20) A host cell comprising a vector of claim 19.

21) A method of producing an antibody of claim 17, comprising culturing a host cell of claim 20 and recovering the antibody from the cell.

22) A pharmaceutical composition comprising an isolated antibody of claim 1 or claim 5 and a pharmaceutically accepted carrier.

23) The use of the isolated human or human-adapted antibody antagonist or fragment thereof that specifically binds Domain I of human ST2L of any one of claims 1-17 in the manufacture of a medicament for the treatment of a ST2L-mediated condition.

24) The use according to claim 23, wherein the ST2L-mediated condition is asthma, airway hyper-reactivity, sarcoidosis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, inflammatory bowel disease, (IBD), eosinophilic esophagitis, scleroderma, atopic dermatitis, allergic rhinitis, bullous pemphigoid, chronic urticaria, diabetic nephropathy, rheumatoid arthritis, interstitial cystitis or Graft Versus Host Disease (GVHD), or

is is associated with inflammatory cell recruitment in lung, goblet cell hyperplasia, increased mucous secretion or mast cell response.

25) The use according to claim 23 or 24, wherein the antibody antagonist comprises:

a) the HCDR1 of SEQ ID NO: 97;

b) the HCDR2 of SEQ ID NO: 114;

c) the HCDR3 of SEQ ID NO: 84;

d) the LCDR1 of SEQ ID NO: 130;

e) the LCDR2 of SEQ ID NO: 90; and

f) the LCDR3 of SEQ ID NO: 134; or

g) the VH of SEQ ID NO: 191 and the VL of SEQ ID NO: 209.